High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition

Thrombosis Research

Volumn 131, Issue 4, 2013, Pages 313-319

  Björkman, Jan Arne ^a   Zachrisson, Helen ^a   Forsberg, Gun Britt ^a   Von Bahr, Helena ^a   Hansson, Göran I ^a   Warner, Timothy D ^b   Nylander, Sven ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Acute coronary syndromes; Aspirin; P2Y 12; Platelet activation; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CLOPIDOGREL; PRASUGREL; PROSTACYCLIN; PURINERGIC P2Y12 RECEPTOR; THROMBOXANE A2; TICAGRELOR;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFICACY; DRUG MEGADOSE; DRUG SCREENING; ENZYME INHIBITION; EX VIVO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; VASCULAR RESISTANCE;

ADENOSINE; ANIMALS; ARACHIDONIC ACID; ASPIRIN; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; THROMBOSIS; TICLOPIDINE; VASCULAR RESISTANCE;

EID: 84875756550     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.01.029     Document Type: Article

References (35)

1. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, and K.K. Fox Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
2. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, and S. Gottlieb Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
3. L. Wallentin, R.C. Becker, A. Budaj, C.P. Cannon, H. Emanuelsson, and C. Held Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
4. C.W. Hamm, J.P. Bassand, S. Agewall, J. Bax, E. Boersma, and H. Bueno ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J 32 2011 2999 3054
5. C. Patrono, F. Andreotti, H. Arnesen, L. Badimon, C. Baigent, and J.P. Collet Antiplatelet agents for the treatment and prevention of atherothrombosis Eur Heart J 32 2011 2922 2932
6. K.W. Mahaffey, D.M. Wojdyla, K. Carroll, R.C. Becker, R.F. Storey, and D.J. Angiolillo Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial Circulation 124 2011 544 554
7. G. Born, and C. Patrono Antiplatelet drugs Br J Pharmacol 147 Suppl. 1 2006 S241 S251
8. J.J. Van Giezen, L. Nilsson, P. Berntsson, B.M. Wissing, F. Giordanetto, and W. Tomlinson Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation J Thromb Haemost 7 2009 1556 1565
9. S. Husted, and J.J. van Giezen Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist Cardiovasc Ther 27 2009 259 274
10. P. Savi, J. Combalbert, C. Gaich, M.C. Rouchon, J.P. Maffrand, and Y. Berger The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A J Thromb Haemost 72 1994 313 317
11. K. Hagihara, M. Kazui, A. Kurihara, H. Iwabuchi, M. Ishikawa, and H. Kobayashi Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite Drug Metab Dispos 38 2010 898 904
12. P.A. Gurbel, K.P. Bliden, K. Butler, M.J. Antonino, C. Wei, and R. Teng Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study Circulation 121 2010 1188 1199
13. P.A. Gurbel, K.P. Bliden, K. Butler, U.S. Tantry, T. Gesheff, and C. Wei Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study Circulation 120 2009 2577 2585
14. R.F. Storey, S. Husted, R.A. Harrington, S. Heptinstall, R.G. Wilcox, and G. Peters Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes J Am Coll Cardiol 50 2007 1852 1856
15. T.D. Warner, S. Nylander, and C. Whatling Anti-platelet therapy: cyclo-oxygenase inhibition and use of aspirin with particular regard to dual anti-platelet therapy Br J Clin Pharmacol 72 2011 619 633
16. T.D. Warner, P.C. Armstrong, N.P. Curzen, and J.A. Mitchell Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists? Heart 96 2010 1693 1694
17. P.C. Armstrong, A.R. Dhanji, A.T. Tucker, J.A. Mitchell, and T.D. Warner Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy J Thromb Haemost 8 2010 613 615
18. P.C. Armstrong, P.D. Leadbeater, M.V. Chan, N.S. Kirkby, J.A. Jakubowski, and J.A. Mitchell In the presence of strong P2Y(12) receptor blockade, aspirin provides little additional inhibition of platelet aggregation J Thromb Haemost 9 2011 552 561
19. N.S. Kirkby, P.D. Leadbeater, M.V. Chan, S. Nylander, J.A. Mitchell, and T.D. Warner Anti-platelet effects of aspirin vary with level of P2Y(12) receptor blockade supplied by either ticagrelor or prasugrel J Thromb Haemost 9 2011 2013 2105
20. K. Bhavaraju, A. Georgakis, J. Jin, T.K. Gartner, Y. Tomiyama, and A. Nurden Antagonism of P2Y12 reduces physiological thromboxane levels Platelets 21 2010 604 609
21. J.A. Jakubowski, M.J. Stampfer, R. Vaillancourt, and D. Deykin Cumulative antiplatelet effect of low-dose enteric coated aspirin Br J Haematol 60 1985 635 642
22. C. Perneby, N.H. Wallén, C. Rooney, D. Fitzgerald, and P. Hjemdahl Dose- and time-dependent antiplatelet effects of aspirin Thromb Haemost 95 2006 652 658
23. F. Santilli, B. Rocca, R. De Cristofaro, S. Lattanzio, L. Pietrangelo, and A. Habib Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin «resistance» J Am Coll Cardiol 53 2009 667 677
24. G.A. FitzGerald, J.A. Oates, J. Hawiger, R.L. Maas, L.J. Roberts II, and J.A. Lawson Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man J Clin Invest 71 1983 676 688
25. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
26. 12 binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis Thromb Res 124 2009 565 571
27. J. Folts An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis Circulation 83 1991 IV3 IV14
28. H. Sillén, M. Cook, and P. Davis Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 878 2010 2299 2306
29. 1α by gas chromatography-mass spectrometry J Chromatogr B Biomed Appl 653 1994 117 122
30. M. Blatnik, and R.C. Steenwyk Quantification of urinary PGEm, 6-keto PGF1α and 2,3-dinor-6-keto PGF1α by UFLC-MS/MS before and after exercise Prostaglandins Other Lipid Mediat 93 2010 8 13
31. J. Jin, and S.P. Kunapuli Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation Proc Natl Acad Sci USA 95 1998 8070 8074
32. S. Nylander, C. Mattsson, S. Ramström, and T.L. Lindahl The relative importance of the ADP receptors, P2Y12 and P2Y1, in thrombin-induced platelet activation Thromb Res 111 2003 65 73
33. H.C. Diener, J. Bogousslavsky, L.M. Brass, C. Cimminiello, L. Csiba, and M. Kaste Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial Lancet 364 2004 331 337
34. S.J. Duffy, B.T. Tran, G. New, R.N. Tudball, M.D. Esler, and R.W. Harper Continuous release of vasodilator prostanoids contributes to regulation of resting forearm blood flow in humans Am J Physiol 274 1998 H1174 H1183
35. S.J. Duffy, S.F. Castle, R.W. Harper, and I.T. Meredith Contribution of vasodilator prostanoids and nitric oxide to resting flow, metabolic vasodilation, and flow-mediated dilation in human coronary circulation Circulation 100 1999 1951 1957